Cargando…

Elevated XRCC5 expression level can promote temozolomide resistance and predict poor prognosis in glioblastoma

Drug resistance and disease recurrence are important contributors for the poor prognosis of glioblastoma multiforme (GBM). Temozolomide (TMZ), the standard chemotherapy for GBM treatment, can methylate DNA and cause the formation of double-strand breaks (DSBs). X-ray repair cross complementing 5 (XR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, I-Neng, Yang, Jen-Tsung, Huang, Cheng, Huang, Hsiu-Chen, Wu, Yu-Ping, Chen, Jui-Chieh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8045174/ https://www.ncbi.nlm.nih.gov/pubmed/33868481 http://dx.doi.org/10.3892/ol.2021.12704

Ejemplares similares

ADAM17 Confers Temozolomide Resistance in Human Glioblastoma Cells and miR-145 Regulates Its Expression
por: Yang, Jen-Tsung, et al.
Publicado: (2023)

Valproic acid-induced amphiregulin secretion confers resistance to temozolomide treatment in human glioma cells
por: Chen, Jui-Chieh, et al.
Publicado: (2019)

Combined elevation of TRIB2 and MAP3K1 indicates poor prognosis and chemoresistance to temozolomide in glioblastoma
por: Wang, Jia, et al.
Publicado: (2019)

Tbx2 confers poor prognosis in glioblastoma and promotes temozolomide resistance with change of mitochondrial dynamics
por: Yi, Fuxin, et al.
Publicado: (2017)

Retraction: Receptor tyrosine kinase AXL is correlated with poor prognosis and induces temozolomide resistance in glioblastoma
por: Wang, Jia, et al.
Publicado: (2019)

Elevated RGMA Expression Predicts Poor Prognosis in Patients with Glioblastoma
por: Phan, Thi Le, et al.
Publicado: (2021)

Significant value of XRCC2 and XRCC9 expression in the prognosis of human ovarian carcinoma
por: Liu, Yi, et al.
Publicado: (2021)

Overexpressed XRCC2 as an independent risk factor for poor prognosis in glioma patients
por: Liu, Zhendong, et al.
Publicado: (2021)

Tumor Microenvironment and Genes Affecting the Prognosis of Temozolomide-Treated Glioblastoma
por: Jang, Yena, et al.
Publicado: (2023)

An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?
por: Teraiya, Milan, et al.
Publicado: (2023)

Poor-Prognosis Patients Affected by Glioblastoma: Retrospective Study of Hypofractionated Radiotherapy with Simultaneous Integrated Boost and Concurrent/Adjuvant Temozolomide
por: Gregucci, Fabiana, et al.
Publicado: (2021)

A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to Temozolomide
por: Chai, Rui-Chao, et al.
Publicado: (2019)

Temozolomide promotes genomic and phenotypic changes in glioblastoma cells
por: Stepanenko, Aleksei A., et al.
Publicado: (2016)

Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients
por: Shields, Lisa B. E., et al.
Publicado: (2015)

TERT Promoter Mutations Lead to High Transcriptional Activity under Hypoxia and Temozolomide Treatment and Predict Poor Prognosis in Gliomas
por: Chen, Chen, et al.
Publicado: (2014)

Temozolomide resistance in glioblastoma multiforme
por: Lee, Sang Y.
Publicado: (2016)

Loss of PTEN Is Not Associated with Poor Survival in Newly Diagnosed Glioblastoma Patients of the Temozolomide Era
por: Carico, Christine, et al.
Publicado: (2012)

Elevation of CXCL1 indicates poor prognosis and radioresistance by inducing mesenchymal transition in glioblastoma
por: Alafate, Wahafu, et al.
Publicado: (2020)

Safety and tolerability of asunercept plus standard radiotherapy/temozolomide in Asian patients with newly-diagnosed glioblastoma: a phase I study
por: Wei, Kuo-Chen, et al.
Publicado: (2021)

Exploring the Mechanism of Adjuvant Treatment of Glioblastoma Using Temozolomide and Metformin
por: Feng, Shao-Wei, et al.
Publicado: (2022)

Association between glioblastoma cell‐derived vessels and poor prognosis of the patients
por: Mei, Xin, et al.
Publicado: (2020)

MLK3 Is Associated With Poor Prognosis in Patients With Glioblastomas and Actin Cytoskeleton Remodeling in Glioblastoma Cells
por: Zhu, Yan, et al.
Publicado: (2021)

A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
por: Chen, Xiaoyue, et al.
Publicado: (2018)

Identification of Differentially Expressed Genes in Different Glioblastoma Regions and Their Association with Cancer Stem Cell Development and Temozolomide Response
por: Hsu, Justin Bo-Kai, et al.
Publicado: (2021)

High Expression of XRCC6 Promotes Human Osteosarcoma Cell Proliferation through the β-Catenin/Wnt Signaling Pathway and Is Associated with Poor Prognosis
por: Zhu, Bin, et al.
Publicado: (2016)

FBW7 is associated with prognosis, inhibits malignancies and enhances temozolomide sensitivity in glioblastoma cells
por: Lin, Jing, et al.
Publicado: (2018)

ACT-10 TREATMENT FOR GLIOBLASTOMA RECURRED AFTER CONCOMITANT CHEMORADIATION THERAPY WITH TEMOZOLOMIDE AND THEIR PROGNOSIS
por: Mori, Kanji, et al.
Publicado: (2019)

Accelerated hyperfractionation plus temozolomide in glioblastoma
por: Kaul, David, et al.
Publicado: (2016)

Strategies of temozolomide in future glioblastoma treatment
por: Lee, Chooi Yeng
Publicado: (2017)

Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma
por: Saha, Dipongkor, et al.
Publicado: (2020)

LncRNA SOX2OT promotes temozolomide resistance by elevating SOX2 expression via ALKBH5-mediated epigenetic regulation in glioblastoma
por: Liu, Boyang, et al.
Publicado: (2020)

Enrichment of superoxide dismutase 2 in glioblastoma confers to acquisition of temozolomide resistance that is associated with tumor-initiating cell subsets
por: Chien, Chia-Hung, et al.
Publicado: (2019)

Suppressing TRAP1 sensitizes glioblastoma multiforme cells to temozolomide
por: Wang, Nan, et al.
Publicado: (2021)

Interfering with mitochondrial dynamics sensitizes glioblastoma multiforme to temozolomide chemotherapy
por: Wang, Nan, et al.
Publicado: (2021)

NETRIN-4 Protects Glioblastoma Cells FROM Temozolomide Induced Senescence
por: Li, Li, et al.
Publicado: (2013)

A Comprehensive Evaluation of the Association between Polymorphisms in XRCC1, ERCC2, and XRCC3 and Prognosis in Hepatocellular Carcinoma: A Meta-Analysis
por: Zhao, Yan, et al.
Publicado: (2019)

Focused Ultrasound-Induced Blood–Brain Barrier Opening to Enhance Temozolomide Delivery for Glioblastoma Treatment: A Preclinical Study
por: Wei, Kuo-Chen, et al.
Publicado: (2013)

Hypomethylation of 111 Probes Predicts Poor Prognosis for Glioblastoma
por: Chen, Qi, et al.
Publicado: (2019)

Six-Transmembrane Epithelial Antigen of Prostate 3 Predicts Poor Prognosis and Promotes Glioblastoma Growth and Invasion
por: Han, Mingzhi, et al.
Publicado: (2018)

Association of XRCC1, XRCC2 and XRCC3 Gene Polymorphism with Esophageal Cancer Risk
por: Kaur, Jagjeet, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j6vd4011obenkq1k1utmrlp44o